Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

References

• World Health Organization. Dengue vaccine: WHO position paper – september 2018. Wkly Epidemiol Rec 2018;36:457–76.
   Google Scholar
• Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–40. doi:10.1056/NEJMoa1800820.
   PubMed Web of Science ®Google Scholar
• Vigne C, Dupuy M, Richetin A, Guy B, Jackson N, Bonaparte M, Hu B, Saville M, Chansinghakul D, Noriega F, et al. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination. Hum Vaccin Immunother. 2017;13(9):2004–16. doi:10.1080/21645515.2017.1333211.
   PubMed Web of Science ®Google Scholar
• Moodie Z, Juraska M, Huang Y, Zhuang Y, Fong Y, Carpp LN, Self SG, Chambonneau L, Small R, Jackson N, et al. Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America. J Infect Dis. 2018;217(5):742–53. doi:10.1093/infdis/jix609.
   PubMed Web of Science ®Google Scholar
• Tran NH, Chansinghakul D, Chong CY, Low CY, Shek LP, Luong CQ, Frago C, Wartel TA, Sun S, Skipetrova A, et al. Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials. Hum Vaccin Immunother. 2019;15(10):2315–27. doi:10.1080/21645515.2019.1578595.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Laot TM, Boaz M, Wartel TA, Crevat D. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials Vaccinol. 2015;4:19–23. doi:10.1016/j.trivac.2015.03.002.
   Google Scholar
• Park J, Archuleta S, Oh M-LH, Shek LP-C, Jin J, Bonaparte M, Frago C, Bouckenooghe A. Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series. Hum Vaccin Immunother. 2020;16:523–29. doi:10.1080/21645515.2019.1661204.
   PubMed Web of Science ®Google Scholar
• Coronel D, Garcia-Rivera EJ, Rivera M, Arredondo-Garcia JL, Dietze R, Perroud AP, Cortés M, Bonaparte M, Zhao J, Tila M, et al. Dengue vaccine booster in healthy adolescents and adults in Latin America: evaluation 4–5 years after a primary 3-dose schedule. Pediatr Infect Dis J. 2019;38(5):e90–e5. doi:10.1097/INF.0000000000002286.
   PubMed Web of Science ®Google Scholar
• Palm A-KE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01787.
   PubMed Web of Science ®Google Scholar
• Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine. 2008;26(45):5712–21. doi:10.1016/j.vaccine.2008.08.019.
   PubMed Web of Science ®Google Scholar
• Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, Wei Liang A, Li Ng J, Yun Toh X, Archuleta S, Wilder-Smith A, et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother. 2013;9(11):2317–25. doi:10.4161/hv.25562.
   PubMed Web of Science ®Google Scholar
• Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg. 2013;88:962–70. doi:10.4269/ajtmh.12-0461.
   PubMed Web of Science ®Google Scholar
• Lee H, Sun Y, Patti-Diaz L, Hedrick M, Ehrhardt AG. High-throughput analysis of clinical flow cytometry data by automated gating. Bioinform Biol Insights. 2019;13:1177932219838851. doi:10.1177/1177932219838851.
   Web of Science ®Google Scholar
• Le Lann L, Jouve P-E,Alarcón-Riquelme M, Jamin C, Pers J-O, Alvarez-Errico D, Azevedo N, Barbarroja N, Buttgereit A, et al. Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. Sci Rep. 2020;10(1):11567. doi:10.1038/s41598-020-68468-3.
   Web of Science ®Google Scholar
• Coronel D, García-Rivera E, Rivera D, Arredondo-García J, Dietze R, Perroud A, Cortés M, Bonaparte M, Wang H, Pagnon A, et al. Immune response persistence and safety of a booster dose of tetravalent dengue vaccine in adolescents and adults who previously completed the three-dose schedule 4–5 years earlier in latin america: a randomized placebo-controlled trial. Pediatr Infect Dis J. 2020; 39(10): 961–968 doi:10.1097/INF.0000000000002830.
   Web of Science ®Google Scholar
• Khodadadi L, Cheng Q, Radbruch A, Hiepe F. The Maintenance of Memory Plasma Cells. Front Immunol. 2019;10:721. doi:10.3389/fimmu.2019.00721
   Google Scholar
• Fink K. Origin and Function of Circulating Plasmablasts during Acute Viral Infections. Front Immunol. 2012;3:78. doi:10.3389/fimmu.2012.00078
   Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9:185–94. doi:10.1038/nri2508.
   PubMed Web of Science ®Google Scholar
• Appanna R, Kg S, Xu MH, Toh Y-X, Velumani S, Carbajo D, Lee CY, Zuest R, Balakrishnan T, Xu W, et al. Plasmablasts during acute dengue infection represent a small subset of a broader virus-specific memory B cell pool. EBioMedicine. 2016;12:178–88. doi:10.1016/j.ebiom.2016.09.003.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum Vaccin Immunother. 2014;10:2853–63. doi:10.4161/21645515.2014.972131.
   PubMed Web of Science ®Google Scholar
• Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008;14:623–28. doi:10.1038/nm.f.1774.
   PubMed Web of Science ®Google Scholar
• Boyd A, Almeida JR, Darrah PA, Sauce D, Seder RA, Appay V, Gorochov G, Larsen M. Pathogen-specific T cell polyfunctionality is a correlate of T cell efficacy and immune protection. PloS One. 2015;10:e0128714. doi:10.1371/journal.pone.0128714.
   PubMed Web of Science ®Google Scholar